Graciela Latalladi Ortega, MD
Internal Medicine · Bayamon, PRNPI 1366626921
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,598 of the $10,811 with a category attached, or 70.3%. AstraZeneca accounts for 60.6% of it on its own, with 18 other manufacturers making up the rest. Among internal medicine clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 212 payments — averaging $51.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$7K
- GSK$1K
- Sanofi$571
- Boehringer Ingelheim$418
- E.r. Squibb & Sons, L.L.C.$367
- Merck$338
- plus $1K from 13 others
What the payments were for
- Consulting fees$3,02328%
- Food & beverage$7,59870%
- Education$1902%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 75 | $6,554 |
| GSK | 54 | $1,367 |
| Sanofi | 13 | $571 |
| Boehringer Ingelheim | 18 | $418 |
| E.r. Squibb & Sons, L.L.C. | 3 | $367 |
| Merck | 8 | $338 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $270 |
| Amgen | 11 | $235 |
| Johnson & Johnson | 4 | $205 |
| Mylan Specialty L.p. | 5 | $127 |
| Sanofi-aventis U.S. LLC | 1 | $98 |
| Boston Scientific | 1 | $83 |
| Shire North American Group Inc | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 1 | $32 |
| Novartis | 1 | $24 |
| Viatris Specialty LLC | 1 | $24 |
| Genentech USA, Inc. | 1 | $23 |
| Pfizer Pharmaceuticals LLC | 1 | $22 |
| PBG Puerto Rico LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,811 in reported general payments places this provider in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 599 | $402,907 |
| FasenraBenralizumab | 41 | $236,017 |
| Dupixent PenDupilumab | 19 | $72,433 |
| TezspireTezepelumab-Ekko | 15 | $67,687 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 90 | $60,085 |
| Breo ElliptaFluticasone/Vilanterol | 103 | $42,397 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 67 | $33,820 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 60 | $28,771 |
| Wixela InhubFluticasone Propion/Salmeterol | 110 | $20,767 |
| Spiriva RespimatTiotropium Bromide | 26 | $13,869 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 44 | $11,588 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 268 | $10,746 |
| Fluticasone Propionate | 532 | $8,935 |
| SymbicortBudesonide/Formoterol Fumarate | 30 | $6,954 |
| Ipratropium Bromide | 180 | $6,673 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,367 | $482,839792 claims |
| AstraZenecaFasenra, Tezspire, Breztri Aerosphere, Symbicort | $6,554 | $370,743176 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $418 | $47,69093 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $32 | $2,62511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.
Other internal medicine in Bayamon
- Sixto MedinaBayamon$15K
- Pedro Roman EyxarchBayamon$9K
- Neisa Torres ReyesBayamon$8K
- Luis FortiBayamon$8K
- Carlos AcostaBayamon$7K
- Jose Aviles MunozBayamon$6K
- Steven CruzBayamon$6K
- Lionel Velez MontijoBayamon$6K
- Wanda Beltran VirellaBayamon$5K
- Nelson VallejoLas Piedras$621K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.